Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 5,030.00
-180.00 (-3.45%)
Jul 21, 2026, 3:30 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 62.62 billion as of July 21, 2026. Its market cap has decreased by -67.64% in one year.
Market Cap
62.62B
Enterprise Value
166.88B
Revenue
16.21B
Ranking
n/a
PE Ratio
n/a
Stock Price
5,030.00
ChartMarket Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 62.62B, a decrease of -82.63%. That is a compound annual growth rate of -28.83%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 20, 2026 | 62.62B | -59.46% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genexine | 106.88B |
| Vaxcell-Bio Therapeutics | 96.40B |
| MedPacto | 92.37B |
| Amicogen | 82.36B |
| iNtRON Biotechnology | 79.35B |
| ENCell | 72.13B |
| CG Invites | 67.97B |
| ORIENT BIO | 52.47B |